Targeting Mitochondrial Proline Dehydrogenase (PRODH) with a Suicide Inhibitor as a Novel Anticancer Strategy by Becker, Beatrice
Dominican Scholar 
Graduate Master's Theses, Capstones, 
and Culminating Projects Student Scholarship 
5-2018 
Targeting Mitochondrial Proline Dehydrogenase (PRODH) with a 
Suicide Inhibitor as a Novel Anticancer Strategy 
Beatrice Becker 
Dominican University of California 
https://doi.org/10.33015/dominican.edu/2018.bio.05 
Survey: Let us know how this paper benefits you. 
Recommended Citation 
Becker, Beatrice, "Targeting Mitochondrial Proline Dehydrogenase (PRODH) with a Suicide 
Inhibitor as a Novel Anticancer Strategy" (2018). Graduate Master's Theses, Capstones, and 
Culminating Projects. 337. 
https://doi.org/10.33015/dominican.edu/2018.bio.05 
This Master's Thesis is brought to you for free and open access by the Student Scholarship at 
Dominican Scholar. It has been accepted for inclusion in Graduate Master's Theses, Capstones, and 
Culminating Projects by an authorized administrator of Dominican Scholar. For more information, 




Targeting Mitochondrial Proline Dehydrogenase (PRODH) with a 
Suicide Inhibitor as a Novel Anticancer Strategy 
By 







A culminating thesis submitted to the faculty of Dominican University of California in 











This thesis, written under the direction of candidate’s thesis advisor and approved by the 
thesis committee and the MS Biology program director, has been presented and accepted 
by the Department of Natural Sciences and Mathematics in partial fulfillment of the 
requirements for the degree of Master of Science in Biology at Dominican University of 
California. The written content presented in this work represents the work of the 
candidate alone. 
 
Beatrice Cortina Becker                                                                  
Candidate                                                                                                   05 / 11 / 2018 
 
Dr. Christopher Benz                                                                      
Thesis Advisor                                                                                           05 / 11 / 2018 
 
Dr. Ekaterina Kalashnikova                                                         
Second Reader                                                                                            05 / 11 / 2018 
 
Dr. Meredith Protas                                                                            














Copyright © 2018, by Beatrice Cortina Becker 




Table of Contents 
 
List of Tables & Figures ......................................................................................................v 
Abstract ............................................................................................................................ viii 
Introduction ..........................................................................................................................1 
Materials and Methods .......................................................................................................18 
Result  ................................................................................................................................25 
In Vitro Study .................................................................................................................25 
Investigating UPR
mt
 Activation ......................................................................................30 
PRODH Enzymatic Assay ..............................................................................................32 








List of Tables 
Table 1 
Frequency of wildtype p53 (p53wt) versus mutated p53 (p53mut) 
found in ER-positive and ER-negative subsets of early-onset and late-
onset breast cancers 
List of Figures 
Figure 1 
(A) PRODH mRNA expression levels across 51 different human breast 
cancer cell lines determined from published microarrays and color 
coded by intrinsic subtype, highest in luminal and lowest in triple-
negative breast cancers. (B) PRODH and GLS1 mRNA levels strongly 
inversely correlated; indicated models are among those being evaluated 
for combination therapy. 
Figure 2 
Induced by p53, mitochondrial PRODH catalyzes the first step of 
proline oxidation to produce the unstable metabolic intermediate, P5C, 
with two electrons transferred into the electron transport chain for 
either ATP production or ROS generation, and downstream 
mitochondrial reactions generating glutamate, α-KG, and NADH. 
Rotenone blocks all Complex 1 oxidation of NADH to NAD. 
Figure 3 
(A) PRODH siRNA knockdown (siPR) in MCF7, ZR-75 and (B) 
DU4475 breast cancer cells induce apoptosis detected by cleaved (c) 
PARP on Western blots, less so in ZR-75-1 cells whose higher PRODH 
levels are more difficult to reduce by siRNA knockdown (A). When 
combined with MI-63 (24-48 h) restoration of p53wt, PRODH 
knockdown in the DU4475 (B) and MCF7 (C) cells produces synthetic 
lethality with marked increase in apoptosis. (D) Viability assay 
demonstrates synthetic lethality effectiveness of L-THFA combined 
with MI-63 in DU4475.  
Figure 4 
Model of human PRODH’s catalytic site containing the tyrosine 
(Y548) and arginine (R564, R563) hydrogen-bonded to (A) PRODH 
competitive inhibitor, (S)-(+)-5-oxo-2tetrahydrofurancarboxylic acid 
(5-oxo, green). The FAD moiety and intercalated water molecule are 
shown in yellow and blue, respectively. PRODH bound to both pre- (B) 
and post-reactive (C) N-propargylglycine structure (PPG, green) 
covalently bound with FAD and showing pocket distortion. 
Figure 5 
Mitochondria isolated from PPG pretreated (15 h) & washed (30 min) 
ZR-75-1 cells cannot metabolize proline, although malate metabolism 
remains unaffected; 5-oxo inhibition is lost by wash out (not shown). 




PPG treatment of ZR-75-1 cells (24-72h). The PRODH suicide 
inhibitor, PPG, following its rapid inhibition of PRODH enzyme 
activity induces a time-dependent selective degradation of PRODH 
protein (30-60%) within 24 to 72 hours of cell culture treatment. 
Mitochondrial complex-1 protein NDUFS1 slightly declines over time, 
but the cytoplasmic FAD containing protein MTHFR does not, and 
tracks with total cell actin levels. 
Figure 7 
Mitochondrial PRODH lost within 24h of PPG without mitochondrial 
destruction. PPG treatment induces early loss of mitochondrial PRODH 
protein before loss of outer mitochondrial membrane or later cell death. 
Top panel untreated ZR-75-1 cells stained for PRODH (red) and 
mitochondrial TOM20 (green). Bottom panel identical to top panel but 
cells treated with 5mM PPG for 24 hours. 
Figure 8 
Cytosolic MTHFR (FAD-containing) protein not affected by PPG 
validates western blot data. Top panel untreated ZR-75-1 cells stained 
for cytosolic MTHFR (red) and PRODH (green). Bottom panel 
identical to top panel but cells treated with 5mM PPG for 24 hours 
Figure 9A 
E3 ligase PARKIN not affected by PPG validates the absence of 
mitophagy. Top panel untreated ZR-75-1 cells stained for PARKIN 
(red) and mitochondrial TOM20 (green). Bottom panel identical to top 
panel but cells treated with 5mM PPG for 24 hours. 
Figure 9B 
Live Cell Imaging of ZR-75-1 cells. Healthy mitochondria (green) 
detected after 24 hour treatment of 5-oxo and PPG using MitoTracker 
intercalating dye, a mitochondria marker. Comparable mitochondria 
marked in green punctate by MitoTracker shows no changes between 
treatments relative to control.  
Figure 9C 
Laser confocal images of ZR-75-1 cells upon 24h PPG treatment 
displays PRODH (green) intensity diminished. Compressed Z stack on 
confocal microscope of ZR-75-1 cells showing PRODH (green) 
intensity diminished on cells treated with 5mM PPG for 24 hours 
Figure 9D 
Western analysis of ZR-75-1 cells treated with 24h 5mM PPG vs. 24h 
5mM 5-oxo compared to vehicle control for their PRODH protein 
levels (67kD) normalized to β-actin (~40kD). Western data confirms 5-
oxo has no significant impact upon PRODH levels; while PPG 
treatment produces significant reduction in PRODH levels, 5-oxo only 
slightly reduces PRODH levels. 
Figure 10 
GRP75 communication with TOM20 in mitochondria is disrupted after 
24h PPG. Top panel untreated ZR-75-1 cells stained for GRP75 (red) 
and mitochondrial TOM20 (green). Bottom panel identical to top panel 




ZR-75-1 cells treated with 24h PPG show elevated levels of HSP60. 
(A) Western blot of ZR-75-1 whole cell lysate probed for HSP60 
(60kD) and normalized to β-actin (~40kD) with C1/C2 control samples. 
(B) Bar graph quantifying normalized HSP60 values relative to β-actin 
Figure 12 
ZR-75-1 cells vehicle and PPG treated given proline and malate to 
metabolize. Graph displays NADH fluorescence measurements in 
vehicle (blue) and PPG treated (red) cells when proline and malate 
substrates are added to 96-well plate. Complex I of the electron 
transport chain is inhibited with Rotenone to prevent NADH oxidation. 
Figure 13 
PRODH protein expression in mouse kidneys (+/- PPG treatment) 
shows PRODH level reduction in PPG treated vs vehicle. Western blot 
showing whole cell lysate from frozen mouse kidneys (PTC1797); 
MCF7-xenografted nu/nu mice treated with vehicle (Veh974, Veh975) 
vs. PPG 50 mg/kg x 3 (qod) in saline intravenously (IV925, IV962), 
intraperitoneally (IP963, IP964) and by oral gavage (PO966, PO967). 
Blot probed for PRODH (67kD) and normalizing mitochondrial protein 
ATP synthase (55kD) 
Figure 14 
PRODH protein expression in mitochondria isolated from mouse 
kidneys (+/- PPG treatments - PTC1797); MCF7-xenografted nu/nu 
mice treated with vehicle vs. PPG 50 mg/kg x 3 (qod) in saline 
intravenously (IV925) and by oral gavage (PO967). Blot probed for 
PRODH (67kD) and normalizing mitochondrial protein ATP synthase 
(55kD) 
Figure 15 
PRODH protein expression in mitochondrial isolated from mouse 
kidneys (+/- PPG treatments - PTC1797). MCF7-xenografted nu/nu 
mice treated with vehicle (975) vs. PPG 50 mg/kg x 3 (qod) in saline 
by oral gavage (PO 966 and 967). Blot probed for PRODH (67kD) and 
normalizing mitochondrial protein Cytochrome C (15kD) 
Figure 16 
PTC-1797 MCF7-xenografted nu/nu. (A) Displays tumor volume 
measurements for nine mice (three per group PO, IV, IP) treated with 
PPG 50 mg/kg x 3 (qod); (B) Averages results per group (PO blue line, 
IV maroon line, IP gray line). Both display PPG treatment initiated at 
day 21 and PPG’s ability to reduce tumor volumes (unpublished data). 
Figure 17 
PTC-1854 MCF7-xenografted nu/nu. Graph displays tumor volume 
measurements for two mice treated with nine daily PO doses of PPG 
(50 mg/kg) – green (3840) and turquoise (3880) lines relative to control 
– blue (3883) line. Dosing started at study day 58 and mice were 
sacrificed at day 66 (unpublished data). 
Figure 18 
PRODH protein expression in mitochondria isolated from mice tumors 
(+/- PPG treatments - PTC1854); MCF7-xenografted nu/nu mice 
treated with vehicle control (3883) vs. PPG 50 mg/kg x 9 daily doses in 
saline by oral gavage (3840, 3880). Blot probed for PRODH (67kD) 
and normalizing mitochondrial protein ATP synthase (55kD). 
viii 
 
Abstract   
Proline dehydrogenase (PRODH) is a p53-inducible inner mitochondrial 
membrane protein linked to electron transport and capable of generating mitochondrial 
glutamate and intracellular ATP, especially under cellular stress conditions. Among a 
panel of 51 human breast cancer cell lines, PRODH and glutaminase (GLS1) expression 
levels were found to be inversely correlated (1) implicating two independent and 
alternative mitochondrial pathways supplying anaplerotic glutamate for cancer cell 
energy production and macromolecular synthesis. Proposing PRODH to be a promising 
cancer therapeutic target, we compared the in vitro cellular effects of PRODH 
knockdown by siRNA as well as competitive (L-tetrahydrofuroic acid, THFA; or 5-oxo-
2-tetrahydrofurancarboxylic acid, 5-oxo) and irreversible/suicide (PPG) inhibitors of 
PRODH using cultured human breast cancer cells. PRODH knockdown or enzymatic 
inhibition each inhibited cell growth and induced variable degrees of apoptosis against 
malignant breast epithelial cell lines (ZR-75-1, DU4475, MCF-7) without affecting 
immortalized and non-malignant breast epithelial cells (MCF-10A). Loss of PRODH 
function produced additive in vitro anticancer effects when combined with either a p53 
upregulator (MI-63) or a glutaminase inhibitor (CB-839) (2). Unlike the competitive 
inhibitors, PPG not only demonstrated irreversible inhibition of PRODH enzymatic 
activity on isolated breast cancer cell mitochondria (ZR-75-1) but it also induced loss of 
mitochondrial PRODH expression prior to its induction of cancer cell apoptosis. 
Computer modeling of PRODH’s enzymatic pocket occupied by either 5-oxo or PPG 
revealed that PPG likely induces molecular distortion, suggesting its unique ability to 
activate apoptosis by first triggering mitochondrial stress; however, it remains unclear 
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whether the cancer cell’s ultimate response to this initial mitochondrial stress is mediated 
by mitophagy or by the mitochondrial unfolded protein response (UPR
mt
). The two 
objectives of this current project address both the mechanistic questions about 
mitochondrial stress induced by the suicide PRODH inhibitor, PPG, as well as a more 
translational question about the in vivo feasibility of systemically administering PPG as a 
potential therapeutic. To address the first objective, we employed confocal intracellular 
imaging to investigate the mitochondrial stress induced by PPG. To address the second 
objective, PPG was administered in vivo to flies and mice (implanted with xenografted 
human breast tumors) to observe both whole organism and tissue-specific effects of this 
mitochondrial stress inducing suicide inhibitor of PRODH. These studies form the basis 
for more extended in vivo preclinical testing of PRODH suicide inhibitors as a potential 






Breast cancer classification  
Breast cancer is currently classified clinically and molecularly by the presence or 
absence of overexpression of three different breast cancer biomarkers: estrogen receptor-
α (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 
(HER2 or ERBB2) (3, 4, 5). In conjunction with their expression, these three biomarkers 
define four primary intrinsic subclasses of breast cancer: luminal A (ER+ and/or PR+, 
HER2-), luminal B (ER+ and/or PR+, HER2+), HER2-enriched (ER- and PR-, HER2+) 
and basal-like (ER-, PR- and HER2-; sometimes referred to as “triple-negative”) breast 
cancers (6, 7). Each of these four biological subclasses of breast cancer is clinically 
distinct with respect to both patient prognosis and treatment approaches. These subtypes 
have been investigated at the molecular level in order to find specialized interventions to 
combat breast cancer tumors that do not respond to treatments or relapse. No single 
therapy works one hundred percent of the time and that is why multiple therapeutic 
strategies are being evaluated in an attempt to produce efficient intervention for tumors 
regardless of their molecular subtype. The search continues for new targeted therapies as 
the field unravels what aspects could be uniform for different types of tumors and not 
necessarily a very specific molecular subtype.  
Breast cancer metabolic reprogramming with dependence on GLS1 or PRODH for 
mitochondrial glutamate production  
Other than the established biomarkers, there is a great need to identify novel 
biomarkers and new drug targets that will potentially improve the clinical outcome of 
breast cancer patients. Bioenergetics and mitochondrial function studies can help answer 
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the question where cancers get their energy from, while manipulating energetics would 
be beneficial for many tumor types, for some of them this could even be a unique 
treatment. There has been a growing appreciation of cancer cell metabolic 
reprogramming as a driving force underlying the biology of many different types of 
cancers, including breast cancer (8, 9). Known for over a half century, the Warburg effect 
first pointed out that cancer cells commonly generate energy mostly via cytosolic 
glycolysis, even under aerobic conditions, rather than by mitochondrial pyruvate 
oxidation (10). 
The replication and growth of cancer cells depends heavily on energetics and 
mitochondrial glutamate production for both cell energy levels and biosynthetic 
reactions; glutamate may be generated by either glutaminase (GLS1) or proline 
dehydrogenase (PRODH) enzymes as their overexpression appears to be inversely 
correlated across different human breast cancer cell lines (Fig. 1) (1). Glutaminase is a 
mitochondrial enzyme transcriptionally upregulated by the oncogene c-MYC, and it 
converts glutamine into glutamate for anapleurosis and ATP production (11).  The 
importance of c-Myc induced GLS1 overexpression in generating cancer cell “glutamine 
addiction” has been well recognized for nearly a decade. In contrast, less appreciated in 
this regard is the critical role of p53wt induced PRODH, the 67 kDa enzyme found within 
the inner mitochondrial membrane (12) that catalyzes the first and most rate-limiting step 
in proline oxidation, a process that in two metabolic steps subsequently leads to 
mitochondrial glutamate production (13). PRODH’s enzymatic product is the unstable 
intermediate P5C, pyrroline-5-carboxylate, releasing two electrons that are immediately 
transferred into the mitochondria’s electron transport chain where they can be used for 
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either ATP production or ROS generation (Fig. 2) (1). If these electrons are optimally 
transported, each molecule of catabolized proline can yield up to 30 ATP molecules (14), 
and further oxidation of P5C by P5CDH yields mitochondrial glutamate (Fig. 2).  
 
Figure 1. (A) PRODH mRNA expression levels (normalized, log2-scaled) across 51 
different human breast cancer cell lines determined from published microarrays (15) and 
color coded by intrinsic subtype, highest in luminal and lowest in triple-negative breast 
cancers (1). (B) PRODH and GLS1 mRNA levels strongly inversely correlated; indicated 









Figure 2. Induced by p53, mitochondrial PRODH catalyzes the first step of proline 
oxidation to produce the unstable metabolic intermediate, P5C, with two electrons 
transferred into the electron transport chain for either ATP production or ROS generation, 
and downstream mitochondrial reactions generating glutamate, α-KG, and NADH. 
Pyruvate oxidation by PDC produces acetyl Co-A and also increases the NADH pool. 
Rotenone blocks all Complex 1 oxidation of NADH to NAD (1). 
 
In naturally occurring organisms, the in vivo use of proline dehydrogenase 
(PRODH) has long been known to be critical for energy production in flies (Drosophila 
melanogaster) and more recently, for stress resistance in worms (16). PRODH was first 
identified in mammals as PIG-6 (p53 inducible gene-6) by Polyak et al (17) and its 
mitochondrial localization was noted during the study of the in vivo importance of proline 
derived from the breakdown of extracellular matrix collagen to sustain Krebs cycle 
generation of ATP (18, 19). Early on, Phang et al. proposed that PRODH served as a 
tumor suppressing mediator of p53wt activity, inhibiting tumor growth by producing 
ROS and inducing apoptosis (8, 10, 11). Subsequent studies called this conclusion into 
question by documenting PRODH’s ability to promote cancer cell survival via 
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anaplerotic glutamate production and mitochondrial ATP production, especially under 
nutrient and oxygen stress conditions (9, 11, 20). Presently, it is thought that proline 
oxidation by PRODH generates either mitochondrial ATP or ROS production, depending 
on the integrity of the electron transport chain, but not as a direct product of PRODH 
enzymatic activity (21). Using human luminal breast cancer cell line models, Benz 
laboratory studies add compelling support to the hypothesis that proline oxidation 
primarily produces ATP as an essential cell survival mechanism (22).  
Tumor suppressor p53, its transcriptional control of PRODH and their regulation by 
MDM2 
Cellular expression of PRODH is predominantly regulated by the transcription 
factor p53, a model first shown when the identity of PRODH was not clear and it was 
referred to as PIG-6 (17). Well established at the time was the fact that p53 is a tumor 
suppressor protein, often referred to as the “guardian of the genome,” serving to 
coordinate cellular responses to genome injury by inducing either cell cycle arrest 
(cytostasis), enabling DNA damage to be repaired, or programmed cell death (apoptosis) 
when DNA damage is too severe to be repaired. In response to DNA damage, p53 protein 
levels are upregulated and transcriptionally induce other DNA damage response genes 
and cell cycle regulating genes including the cyclin dependent kinase 1 (CDK1) inhibitor 
and p21 that together initiate cell cycle arrest (21), allowing other genes to assess the 
extent of genome damage and thereby determine the cell’s ultimate fate: apoptosis versus 
cytostasis. If the DNA damage can be repaired, p53 also activates the necessary repair 
mechanisms; but if DNA damage cannot be repaired, p53 further signals the cell to 
undergo apoptosis, preventing the damaged DNA to be passed onto the next generation. 
The cellular decision between cytostasis and apoptosis following activation of the 
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p53 pathway has important implications for tumor progression and therapy. In many 
cancer cells, where p53 is mutated, their ability to transcriptionally regulate cell fate is 
lost, allowing those cancer cells to continue dividing and surviving in the face of genomic 
damage, in fact, further facilitating their development of additional oncogenic mutations 
(23). In other cancer cells, including most luminal and HER2+ breast cancers, p53 is not 
mutationally inactivated but rather its level of protein expression is often kept suppressed 
by the overexpression of MDM2, an E3 ubiquitin-protein ligase that causes the 
constitutive proteosomal degradation of p53 (21, 23). It has been observed in human cell 
line models of luminal and HER2+ subtypes specifically, that these express higher 
transcript levels of PRODH and wildtype p53 tumor suppressor gene (p53wt), while 
triple-negative breast cancers most frequently express mutated versions of p53 (p53mut).  
Largely because of the frequent incidence of luminal breast cancer, approximately 
75% of breast cancers overall express wildtype p53 protein (p53wt) (23, 24) and do not 
express any mutated p53 (p53mut) (Table 1) (24). In such ER+ breast cancers, the 
frequency of p53mut can be as low as 10%, while HER2+ breast cancers have a higher 
p53mut frequency that can reach 40%; in contrast, triple-negative breast cancers have a 
p53mut frequency exceeding 70% (24). Currently studied by the Benz group, the 
endogenous level of expression of p53wt can be upregulated by 5-10 fold following 
treatment with a p53 restoring drug such as an MDM2 inhibitor (e.g. Nutlin or MI-63) in 
both normal and malignant cells (25). As a result, this p53wt induction by an MDM2 
inhibitor also increases the expression of various p53 inducible genes such as p21 and 
PRODH, causing changes in mitochondrial bioenergetics and triggering either cytostasis 
(in normal cells) or apoptosis (in cancer cells) (1).  
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Triple-negative breast cancers that express p53mut are not sensitive to an MDM2 
inhibitor; rather, they are frequently associated with c-Myc oncogene overexpression 
which transcriptionally induces glutaminase (GLS1) expression, causing these breast 
cancers to be glutamine-addicted by which much of their tumor cell energy comes from 
mitochondrial glutamate production (Fig. 2), rendering them therapeutically susceptible 
to another inhibitor studied by the Benz group, a glutaminase (GLS1) inhibitor like 
Calithera’s CB-839 (1). While luminal breast cancer cells that express p53wt but lack c-
Myc overexpression are similarly dependent on mitochondrial glutamate production for 
energy and synthetic reactions, their glutamate production comes from p53wt induced 
PRODH and not from GLS1 overexpression. These differences help explain the inverse 
relationship observed between GLS1 and PRODH transcript expression observed across 
luminal vs triple-negative breast cancer cell line models (Fig. 1). These differences also 
suggest that, regardless of the breast cancer subtype, simultaneously inhibiting both 
PRODH and GLS1 pathways might result in a more complete suppression of 
mitochondrial glutamate levels and therefore serve as a more effective and general breast 




Table 1. Frequency of wildtype p53 (p53wt) versus mutated p53 (p53mut) found in ER-
positive (ERpos) and ER-negative (ERneg) subsets of early-onset and late-onset breast 
cancers (24).  
 
 
Cancer cell responses to PRODH protein manipulations  
Energetics is really important for cancer cells and several manipulations have 
been attempted in order to prevent proline catabolism to limit both mitochondrial 
glutamate and ATP production in such cancer cells. In targeting proline catabolism as a 
potential cancer therapeutic, the Benz group has studied different approaches including 
genetically knocking down PRODH and P5CDH enzymes, and blocking PRODH’s 
enzymatic activity with competitive and suicide inhibitors, all focusing to reduce breast 
cancer cell growth and viability.  
Addressing the strategic question of whether to target PRODH or the next 
enzymatic target involved in mitochondrial proline catabolism and glutamate production, 
P5CDH, Benz group investigators knocked down P5CDH and evaluated the knockdown 
effect on cell viability in combination with MI-63 treatment, and observed less c-PARP 
production (PARP cleavage, reflecting apoptosis) when compared to PRODH 
knockdown combined with MI-63; suggesting that targeting PRODH would lead to 
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greater antitumor activity than targeting a different  mitochondrial enzyme in the same 
proline catabolic pathway (1, 25). Results of PRODH knockdown by siRNA have shown 
enhanced apoptosis in human breast cancer cells lines of low (MCF-7) and high (ZR-75-
1) PRODH transcript levels, respectively (Fig. 3A). Increased levels of apoptosis 
occurred in MCF-7 and DU4475 (characterized by their very low PRODH expression) 
breast cancer cells when PRODH knockdown was combined with 24-48 hours of MI-63 
treatment (Fig. 3B-3C). These results show that PRODH knockdown combined with the 
upregulation of p53 (MI-63 treatment) produces a 4-fold greater capacity to eradicate 
breast cancer cells compared to MI-63 treatment alone.  
The current focus of the Benz laboratory became a comparison of luminal breast 
cancer cell responses when treated with either competitive or suicide PRODH inhibitors 
(26). In order to investigate the mechanistic rationale for focusing on an 
irreversible/suicide PRODH inhibitor rather than a competitive PRODH inhibitor, Benz 
group medicinal chemistry collaborators first produced a human PRODH structural 
model for drug discovery and design purposes, where primitive bacterial amino acids 
were replaced with human ones (2). Tanner et al. first crystalized bacterial PRODH in the 
oxidized state containing FAD along with the competitive proline analog, L-
tetrahydrofuroic acid (L-THFA) (27); no mammalian or human PRODH structure was 
available before or has since become available. Studies were performed by inhibiting the 
human PRODH structural model with L-THFA, another competitive inhibitor, 5-oxo-2-
tetrahydrofurancarboxylic acid (5-oxo) and the newly synthesized and patented inhibitor 
N-propargylglycine (PPG) (26). Greater hydrogen-bond affinity to PRODH’s catalytic 
site was observed with the newer competitive inhibitor, 5-oxo, relative to a model bound 
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to the previously described proline analog, L-THFA (27). However, the difference 
between reversible and irreversible PRODH inhibitors (5-oxo vs. pre- and post-reactive 
states of PPG) is that the catalytic pocket bound with 5-oxo is structurally undistorted, 
whereas the post-reactive pocket where PPG is covalently linked to the FAD moiety is 
structurally distorted (Fig. 4).  
Numerous assessments of these PRODH inhibitors have been investigated and the 
facts are suggestive of PPG being a more interesting and superior inhibitor to target 
proline catabolism than competitive inhibitors. First, mitochondria from ZR-75-1 cells 
that were treated with 5-oxo exhibit the same production of NADH as cells treated with 
PPG, when given the substrate proline to metabolize. However, the reversible 
competitive inhibitor 5-oxo is washed away when mitochondria are rinsed losing the 
inhibitory effect while the irreversible inhibitor PPG remains bound (Fig. 5), inhibiting 
proline metabolism. Secondly, PRODH inhibition creates a synthetic lethal therapeutic 
opportunity by combining PPG with either an MDM2 inhibitor or a glutaminase inhibitor 
(1, 2, 25) owing to the ability of the competitive inhibitor L-THFA to act in a similar 
synthetic lethal interaction with an MDM2 inhibitor and capable to significantly reduce in 
vitro growth (% viability) of DU4475 cells compared to either treatment administered 
alone (Fig. 3D). Thirdly, supplementary data demonstrate the ability of the suicide 
inhibitor PPG to promote PRODH degradation in ZR-75-1 cells days before any changes 
in mitochondrial complex-1 protein, NDUFS1 could be detected; and in the absence of 
any degradation occurring in an extra-mitochondrial FAD-containing enzyme, 
methylenetetrahydrofolate reductase (MTHFR) (Fig. 6). This selective degradation of 
mitochondrial PRODH is only seen in cells treated with PPG, and was not observed after 
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treatment with competitive inhibitors given at a dose able to fully inhibit PRODH 
enzymatic activity. Lastly, it has been observed that non-malignant epithelial cells (MCF-
10A) do not appear to be susceptible to the growth inhibiting consequences of PRODH 
inhibition, raising the provocative suggestion that normal cells within an organism treated 
in vivo with a PRODH suicide inhibitor might actually benefit via mitohormesis, an 
organismal response to sublethal mitochondrial stress, capable of activating cytosolic 
signaling pathways and ultimately nuclear gene expression (28) enhancing cell stress 
resistance and improving healthspan.  
Two different but plausible cellular responses to any type of mitochondrial stress 
are mitochondrial unfolded protein response (UPR
mt
) and mitophagy, the degradation of 
mitochondria by autophagy. The induction of mitochondrial PRODH decay observed 
with PPG treatment, and not observed following either L-THFA or 5-oxo treatments, 
understandably has consequences to the mitochondria. UPR
mt 
is a conserved cellular 
stress response initiated by loss of protein homeostasis (proteostasis) induced by mis-
/unfolded proteins within the mitochondria and followed by a specific pattern of 
intracellular cell signaling and transcription that includes induction of mitochondria-
specific chaperones (29). UPR
mt 
promotes stabilization and recovery of stressed 
mitochondria while mitophagy serves to remove the most severely damaged of these 
essential organelles. Often beginning with the same initiating response to stress, such as 
loss of mitochondrial protein import and outer membrane accumulation of the ubiquitin 
ligase PARKIN, a cell’s net accumulation and severity of stressed mitochondria appears 
to determine whether either UPR
mt
 or mitophagy will ensue.  These alternate 
mitochondrial fates are difficult to predict but are later associated with different cell 
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signals and pathways, and can subsequently be distinguished by determining whether 
there is mitochondrial loss preceded by the selective degradation of a mitochondrial 
protein like PRODH.  
Unfolded protein response is a difficult mechanism to prove definitively due to 
the lack of absolute molecular criteria that can identify the mechanism in progress, as 
there are no set of consensus criteria and reagents currently available to definitively prove 
or disprove that UPR
mt
 is occurring, apart from the alternative mitochondrial 
consequence, mitophagy. Yet, the induction of the corrective mitochondrial chaperone 
HSP60 appears to be one specific cellular manifestation of the UPR
mt
 (2, 26). As a 
chaperone protein, HSP60 surveils cells and their environment in search of misfolded or 
unfolded proteins, and literature review indicates that HSP60 gets induced as a part of the 
early set of steps triggering the UPR
mt
. Currently, the primary evidence that UPR
mt
 
occurs in response to PPG treatment is that mitochondrial PRODH decay takes place 
within 120 minutes of the PPG treatment and in the absence of ensuing mitochondrial 
destruction or the extra-mitochondrial decay of other FAD-containing enzymes (Fig. 6). 
In this ability to induce UPR
mt
, PPG appears to be a superior anticancer candidate relative 
to competitive PRODH inhibitors, L-THFA and 5-oxo that do not induce the same target 
enzyme decay, which is expected to permanently minimize the cancer cell’s ability to 
generate ATP and glutamate for growth, replication and metastatic spread (1). Thus, a 
cancer cell’s dependence on glutamine and anaplerotic ATP production provides support 




Figure 3. (A) PRODH siRNA knockdown (siPR) in MCF7, ZR-75 and (B) DU4475 
breast cancer cells induce apoptosis detected by cleaved (c) PARP on Western blots, less 
so in ZR-75-1 cells whose higher PRODH levels are more difficult to reduce by siRNA 
knockdown (A). When combined with MI-63 (24-48 h) restoration of p53wt, PRODH 
knockdown in the DU4475 (B) and MCF7 (C) cells produces synthetic lethality with 
marked increase in apoptosis (c PARP). (D) Viability assay demonstrates synthetic 
lethality effectiveness of L-THFA combined with MI-63 in DU4475 (1). Figures 






Figure 4. Model of human PRODH’s catalytic site containing the tyrosine (Y548) and 
arginine (R564, R563) hydrogen-bonded to (A) PRODH competitive inhibitor, (S)-(+)-5-
oxo-2tetrahydrofurancarboxylic acid (5-oxo, green). The FAD moiety and intercalated 
water molecule are shown in yellow and blue, respectively. PRODH bound to both pre- 
(B) and post-reactive (C) N-propargylglycine structure (PPG, green) covalently bound 
with FAD and showing pocket distortion (1). Figure presented at 2015 & 2017 AACR 
annual meetings (2, 22).  
 
 
Figure 5. Mitochondria isolated from PPG pretreated (15 h) & washed (30 min) ZR-75-1 
cells cannot metabolize proline, although malate metabolism remains unaffected; 5-oxo 
inhibition is lost by wash out (not shown). 1mM Proline added first, followed by 1mM 




Figure 6. PPG treatment of ZR-75-1 cells (24-72h). The PRODH suicide inhibitor, PPG, 
following its rapid inhibition of PRODH enzyme activity induces a time-dependent 
selective degradation of PRODH protein (30-60%) within 24 to 72 hours of ZR-75-1 
culture treatment. Mitochondrial complex-1 protein NDUFS1 slightly declines over time, 
but the cytoplasmic FAD containing protein MTHFR does not, and tracks with total cell 
actin levels (1). Figure presented at 2017 AACR annual meeting (22).  
 
Addressing the question of whether administering in vivo a suicide inhibitor like 
PPG, at a dose sufficient to inhibit PRODH and induce its mitochondrial decay, is at all 
feasible and capable of being tolerated in an intact organism, collaboration between the 
Benz and Jasper laboratories at the Buck Institute for Research on Aging generated data 
in Drosophila melanogaster shown in the attached video. Since flies use proline 
metabolism to power their flight muscles (16), flies with genetic knockout of PRODH are 
viable but unable to fly, displaying the “Sluggish-A” phenotype. After 48 hours of PPG 
intake (administered orally as 5mM in sucrose solution), treated flies mimic the 
“Sluggish-A” phenotype (right tube) with reduced flight but without any observed loss of 
viability or fertility. On the other hand, control flies (fed sucrose with DMSO vehicle but 
without PPG) showed normal flight activity and health identical to that of wild type flies 
(left tube). The applied and widely used fly climbing assay is a well-accepted measure of 
16 
 
health; especially in assessing neuronal and muscular decline (30). This in vivo fly 
response and Sluggish-A phenotype produced within 48 hours of PPG administration 
supports the conclusion that in flies, PPG can be ingested orally at a bioavailable dose 
enabling drug transit to a distant organismal site (e.g. wings and flight muscles) and 
achieving in vivo concentration sufficient to produce a prolonged and significant loss of 
cellular PRODH enzymatic activity (e.g. need for cellular flight muscle function).  
  
These fly studies formed the basis for further investigation if PPG can similarly 
be administered in vivo at a bioavailable dose that will be tolerated by mammals (such as 
mice). Since this project’s inception, other investigators have recently begun considering 
PRODH inhibition as a potential cancer treatment strategy. Very recently, Elia et al 
examined the effect of using a competitive PRODH inhibitor (L-THFA) on either 2D 
(monolayer) or 3D (spheroid) growing cancer cells in vitro, reasoning that 3D cell growth 
might be a better in vitro simulation of in vivo cancer metastasis (31).  These 
investigators demonstrated that the relative hypoxia and nutrient deficiency of cancer 
cells growing in 3D spheroids actually produced 3-fold more cellular PRODH compared 
to the same cancer cell growing in 2D monolayers, again supporting the need to consider 
conducting experiments employing PRODH inhibitors in vivo where the stress conditions 
of cancer cell growth are likely more severe than those present under standard in vitro 
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cancer cell growth conditions, and where cancer cell dependence on PRODH enzymatic 
activity may be much greater.   
Moving beyond this most recent work from other investigators, we hoped to 
demonstrate that a PRODH inhibitor like PPG when administered in vivo could be 
tolerated by mammals at a bioavailable dose that would also produce mitochondrial 
decay of PRODH in an organ system or implanted tumor. The focus of this study on 
PRODH, whose expression and enzymatic activity is mitochondrially localized, is not 
necessarily restricted to any specific breast cancer subtype, or even breast cancer vs. 
other types of epithelial malignancies. In general, the link between cancer and 
mitochondrial function is that mitochondrial glutamate produced by proline 
dehydrogenase powers cancer cells, therefore targeting mitochondrial energetics in 
glutamate-addicted cancer cells produces a powerful approach to combat luminal breast 
cancer. Inhibiting PRODH alone only temporarily targets proline catabolism whereas 
inhibiting PRODH with a suicide inhibitor like PPG achieves a higher level of 
commitment where PRODH is essentially eradicated hindering its ability to generate 
ATP and mitochondrial glutamate. All the preliminary data at this point suggest PRODH 
protein levels can be targeted molecularly in order to lessen the energy used to fuel 




Methods & Materials  
 Reagents/antibodies/drugs and PPG synthesis   
The immunoblotting antibody anti-PARP/cPARP (46D11) rabbit monoclonal was 
purchased from Cell Signaling (Danvers, MA). ERα mouse monoclonal (clone F-10), 
rabbit polyclonal and β-actin mouse monoclonal (C4) antibodies were purchased from 
Santa Cruz Biotechnology (Santa Cruz, CA). The goat anti-mouse secondary HRP-
conjugated antibody was purchased from Bio-Rad Laboratories, Inc. (Hercules, CA); the 
α-tubulin mouse monoclonal antibody (T9026) and 5-oxo-2-tetrahydro-furancarboxylic 
acid (5-oxo proline dehydrogenase inhibitor) from MilliporeSigma (St. Louis, MO). The 
following were purchased from Santa Cruz Biotechnology: mouse monoclonal PRODH 
antibody (A-11); mitochondrial mouse monoclonal NDUFS1 (E-8); mitochondrial mouse 
monoclonal Rieske FeS IgG (A-5). The NDUFS1 Rabbit Polyclonal Antibody was 
purchased from ProteinTech
TM 
(Rosemont, IL). The Alexa 488 goat anti-mouse and 
Alexa 594 goat anti-rabbit secondary antibodies were purchased from Life Technologies 
(Thermo Fisher Scientific, Carlsbad, CA). The mouse anti ATP-synthase α and mouse 
anti-cytochrome C were purchased from BD Biosciences Transduction Labs (San Jose, 
CA).  
PPG was synthesized in two-day process: 5ml of DEPC water mixed with 5 
grams of propargylamine (MilliporeSigma) over 5 ml of cold water plus the slow 
addition of 2 grams of iodoacetic acid (stored at -20
o
C) before overnight incubation at 
room temperature. Thermo Fisher Scientific™ Savant™ SPD131DDA SpeedVac™ 
Concentrator was used to dry down volume and sample was divided into Eppendorf tubes 
to dry on SpeedVac. Samples were pooled together and 2.5mL of ethanol was added, 
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followed by 30.5mL of acetone and 3.25mL of ethanol. The resulting precipitate was 
dried and washed extensively using a Buchner funnel. The dried powder was validated by 
HPLC-mass spectrometry and NMR by our collaborator Dr. Bryan Cowen at the 
University of Denver, Denver, Colorado.  
 Cell Culture Growth, Treatment and Harvest of Human Breast Cancer Cell 
Lines   
MCF-7 and ZR-75-1 human breast cancer cell lines were purchased from ATCC 
(American Type Culture Collection, Manassas, VA) and grown in RPMI medium 
supplemented with 10% fetal bovine serum (Cellgro, Manassas, VA). Experimental cells 
were treated with 5mM N-propargylglycine in RPMI medium supplemented with 10% 
fetal bovine serum for 12, 24, 48, 72, or 96 hours. Optimal concentration determined in 
the previous dose dependent studies (1). Control and treated cells were scrapped in 
0.3mL of 2X SDS buffer (2% SDS, 100mM NaCl and 20mM Tris, pH 7.7) and cell 
lysates sonicated with Thermo Fisher Scientific 550 Sonic Dismembrator, prior to gel 
electrophoresis and Western blot analysis.  
 Cell live imaging using MitoTracker under Laser Confocal Microscopy  
ZR-75-1 cells treated with PRODH inhibitors (5mM 5-oxo and 5mM PPG) were 
harvested at 24, 48 and 72 hours of cell culture treatment on glass bottom microwell 
dishes MatTek Corporation (P35G-1.5-14-C) in RPMI media. 2.5µL of MitoTracker® 
Green FM Molecular Probes (Cell Signaling Technology) on 2 mL of charcoal stripped 
media (Gibco, Thermo Fisher Scientific, Carlsbad, CA) were added to ZR-75-1 cells (30 
minute incubation). NucBlue
TM 
Live Stain Ready Probes
TM
 reagent with DAPI 
(Invitrogen by Thermo Fisher Scientific) stained the nuclei of cells.  
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 Gel Electrophoresis, Western analysis and Immunoassays with Antibodies   
Cell lysates ran on Novex™ NuPAGE™ 4-12% Bis-Tris Protein Gel (Invitrogen™ 
Carlsbad, CA) using molecular weight markers (Amersham Full-Range Rainbow
TM
 
Recombinant Protein (GE Healthcare, San Ramon, CA) and transferred to Immobilon® - 
P nitrocellulose membrane (MilliporeSigma, St. Louis, MO). The membrane was blocked 
with 4% non-fat dry milk in 1X TBST, incubated with primary antibody (PRODH mouse 
monoclonal, 1µL/mL) overnight and β-actin (1µL/mL) for two hours, washed three times 
with 1X TBST, incubated with goat anti-mouse IgG secondary antibody conjugated to 
horse radish peroxidase (HRP) (0.1µL/mL) for one hour, and washed three times with 1X 
TBST before developing it with SuperSignal® West Pico Stable Peroxide Solution and 
West Pico Luminol/Enhancer Solution (Thermo Scientific). Chemiluminescent signal 
was captured on film and developed with Konica SRX-101A Medical Film Processor 
(Konica Corporation, Taiwan). Images were analyzed using ImageJ FIJI software (US 
National Institutes of Health, Bethesda, MD) (32). Relative protein levels were calculated 
by subtracting the intensity of each band from the background intensity and compared to 
β-actin and α-tubulin total protein intensity. 
 Isolating mitochondrial from ZR-75-1 cells   
Human breast epithelial cell lines, malignant ZR-75-1, DU4475, MCF7 and non-
malignant MCF10A, were expanded in vitro and suspended in DMEM or RPMI media 
supplemented with 5% fetal bovine serum. Cells were treated with 5mM of either 
PRODH inhibitor (5-oxo or PPG) for 24, 48 and 72 hours, and harvested for 
mitochondria isolation. ZR-75-1 cells cultured in RPMI medium (control and 5mM PPG 
treated) were scraped in 1.2mL mitochondria isolation buffer (250mM sucrose, 10mM 
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Tris-HCl pH 7.4, 0.1mM EGTA, and deionized water) and homogenized with 50 strokes 
of a Dounce homogenizer. Samples with loose nuclei checked on an Olympus ULWCD 
Phase Contrast Microscope Condenser (20X magnification) were transferred to 
Eppendorf tubes and centrifuged for 6 minutes at 3,500 revolutions per minute (RPM) to 
pellet nuclei. Supernatant was centrifuged for 10 minutes at 13,000 RPM to pellet 
mitochondria. Nuclear pellet was solubilized in 2X SDS lysis buffer [100 mM NaCl, 20 
mM Tris pH 7.5, 2% (by weight) SDS, DEPC water] and sonicated before freezing. 
Mitochondrial pellet was resuspended in 30-50 µL mitochondria isolation buffer and kept 
on ice for further analysis.  
 Mitochondrial PRODH enzymatic assay 
Mitochondrial NADH levels were measured by fluorescence spectrometry as a 
function of substrate and inhibitor treatment. Following substrate addition (proline and/or 
malate) to mitochondrial reactions in a 96-well plate format incubated at 37°C, a 15 
minute time course measurement of NADH fluorescence was implemented (Fig. 5). 
Rotenone inhibited Complex 1 of the electron transport chain, blocking NADH oxidation 
(conversion to NAD
+
). 30µL of resuspended intact mitochondria mixed with 165µL of 
4mg/mL rotenone (MilliporeSigma, St Louis, MO) in KHE buffer (120mM KCl, 3mM 
HEPES, 5mM KH2PO4 pH 7.2) (195µL final volume) was transferred to a 96-well plate. 
5µL of 40mM proline and/or 40mM malate were added to alternating wells and levels of 
NADH accumulated per reaction were determined using the PHERAStar FS fluorescent 
plate reader (BMG LABTECH GmbH, Offenburg, Germany) as described in detail in 
Gonçalves et al (21). Two of the wells received 5µL of 5mM PPG in Diethyl 
pyrocarbonate (DEPC) water (GeneMate) immediately before adding substrates.  
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 Fly treatment and study – testing PPG in Drosophila melanogaster 
At 7 days of age, male Oregon Red flies (Fly Base, Oregon-R, Roseburg, OR) were 
starved for 2 hours to synchronize feeding. Flies were transferred to vials (20/vial) 
containing 500µL of 5% w/v sucrose in water ± 5mM PPG absorbed in Whatman filter 
paper. Activity levels and survival were monitored 2X daily, and geotaxis measured daily 
by tapping flies to the bottom of the vial to assess climbing assay (30). 100µL liquid 
standard fly food was supplemented daily. Experiments were also performed in slgA null 
mutant flies (16) that lack the PRODH enzyme.  
 Xenografted mouse treatment and study (include health assessment, tumor 
measurements, sacrifice and snap freezing of organs/tumors)   
The Office of Ethics and Compliance at UCSF approved the IACUC protocol 
(approval #AN142193-02A) for animal studies PTC1797 and PTC1854 entitled “In Vivo 
Evaluation of Experimental Anti-Cancer Therapeutics; UCSF Preclinical Therapeutics 
Core” performed at the UCSF Comprehensive Cancer Center’s Preclinical Core Facility, 
San Francisco, California, by Core Director, and Benz group collaborator, Dr. Byron 
Hahn, MD, PhD. Detailed methodologic description of these experimental MCF-7 
xenograft systems are provided in Scott et al., OncoTarget 2017 (33), a publication that 
reported on tumor ER expression and did not address or describe the effects of PPG 
administration, as being reported now.  
From nude mouse xenograft studies PTC1797, implanted with MCF7-xenografts, we 
isolated kidney whole cell lysate and kidney mitochondria for PRODH protein analysis. 
Vehicle mice were given vehicle saline solution (naïve mouse 970 and vehicle mice 
labeled 971, 974, 975) vs. PPG 50mg/kg three times a day, every other day for nine days, 
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by oral gavage (mice labeled 965, 966, 967), intravenously (mice labeled 962, 925, 968) 
and intraperitoneally (mice labeled 963, 964, 969). Two to three hours after third 
treatment, mice were sacrificed and organs (lung and kidneys) harvested in liquid 
nitrogen. From nude mouse xenograft studies PTC1854, implanted with MCF7-
xenografts, we isolated tumor whole cell lysate and tumor mitochondria for PRODH 
protein analysis. Mice were administered daily doses of 50mg/kg PPG for 9 consecutive 
days by oral gavage. The control tumor-bearing mouse (#3883) was gavaged with saline 
solution daily, and started out with a slightly larger tumor on study day 58. Two mice 
(#3840 and #3880) each received 50mg/kg of PPG via oral gavage daily beginning 
4/14/16 (study day 58) for nine days, ending 4/22/16 (study day 66). Tumor sizes were 
monitored before excision. Both studies were conducted to evaluate PPG’s bioavailability 
and animal tolerance.  
 Isolating mitochondria from mice experiment 
Mice kidneys and tumors were pulverized under liquid nitrogen using 0.6mL 
mitochondrial isolation buffer with mortar and pestle. Samples were transferred to sterile 
Eppendorf tubes with another 0.6mL of mitochondrial isolation buffer and pipetted 
up/down gently, then transferred to Wheaton™ Dounce Tissue Grinders (150 strokes 
applied). Homogeneous cell lysates were centrifuged for 6 minutes at 3,500 RPM to 
pellet the nuclei. Supernatant was centrifuged for 10 minutes at 13,000 RPM to pellet 
mitochondria and those resuspended gently in 30µL of mitochondrial isolation buffer.  
 Laser Confocal Imaging Protocol & Immunocytochemistry Assays  
Cells imaged using Zeiss LSM 780 confocal microscope (Zeiss, Dublin, CA) with 
constant temperature enclosure and CO2 regulation using 63X oil magnification in all 
24 
 
experiments. ZR-75-1 cells plated in 4-well glass slides from Lab-Tek®II 
(MilliporeSigma, St. Louis, MO) were treated with either 5mM PPG or 5mM 5-oxo for 
24-48 hours. Cells were crosslinked with 4% paraformaldehyde in PBS (VWR, Radnor, 
PA) and blocked with IGEPAL® CA-630 NP 40 (MilliporeSigma, St. Louis, MO) made 
10% in DEPC water, mixed with 5% normal goat serum (Cell Signaling Technologies, 
Danvers, MA) in PBS. Next, cells probed with a variety of primary and secondary 
antibodies, and ProLong® Gold antifade reagent with DAPI (Molecular Probes by Life 
Technologies, Thermo Fisher Scientific, Carlsbad, CA) were imaged at 63X oil 
magnification. Bitplane Imaris Software (Oxford Instruments, Concord, MA) used for 3D 





In Vitro Study Results  
Confocal microscopy used to examine the effects 5mM PPG treatment on ZR-75-
1 cells for 24 hours and to evaluate the number of mitochondria and PRODH protein 
expression relative to other proteins, show a loss of PRODH protein intensity compared 
to vehicle treated cells (Fig. 7). Used as a marker for mitochondrial number, the intensity 
of TOM20, a protein located in the mitochondrial outer membrane remained unchanged 
throughout the experiment. The cytosolic enzyme Methylenetetrahydrofolate reductase 
(MTHFR) previously identified as a protein structurally similar to PRODH both in its 
structural organization and for containing a FAD moiety (13) remained unchanged 
throughout the experiment, while PRODH intensity was dramatically reduced (Fig. 8). 
The merged signal between MTHFR (cytoplasmic) and PRODH (mitochondrial) showed 
no overlap. Mouse monoclonal and rabbit polyclonal PRODH antibodies used produced 
similar results, discarding any possible antibody artifacts.  
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Figure 7. Mitochondrial PRODH lost within 24h of PPG without mitochondrial 
destruction. PPG treatment induces early loss of mitochondrial PRODH protein before 
loss of outer mitochondrial membrane or later cell death. Top panel untreated ZR-75-1 
cells stained for PRODH (red) and mitochondrial TOM20 (green). Bottom panel identical 




Figure 8. Cytosolic MTHFR (FAD-containing) protein not affected by PPG validates 
western blot data. Top panel untreated ZR-75-1 cells stained for cytosolic MTHFR (red) 
and PRODH (green). Bottom panel identical to top panel but cells treated with 5 mM 




Figure 9A. E3 ligase PARKIN not affected by PPG validates the absence of mitophagy. 
Top panel untreated ZR-75-1 cells stained for Parkin (red) and mitochondrial TOM20 




Figure 9B. Live Cell Imaging of ZR-75-1 Cells. Healthy mitochondria (green) detected 
after 24 hour treatment of 5-oxo and PPG using MitoTracker intercalating dye, a 
mitochondria marker. Comparable mitochondria marked in green punctate by 






Figure 9C. Laser confocal images of ZR-75-1 cells upon 24h PPG treatment displays 
PRODH (green) intensity diminished. Compressed Z stack on confocal microscope of 
ZR-75-1 cells showing PRODH (green) intensity diminished on cells treated with 5mM 
PPG for 24 hours.  
 
 
Figure 9D. Western analysis and quantification of ZR-75-1 cells treated with 24h 5mM 
PPG versus 24h 5mM 5-oxo compared to vehicle control for their PRODH levels (67kD) 
normalized to β-actin (~40kD). Western data confirms that 5-oxo has no significant 
impact upon PRODH levels. While PPG treatment (5mM) produces significant reduction 
in PRODH levels, 5-oxo (5mM) only slightly reduces PRODH levels.  
 
The localization of PARKIN, an E3 ubiquitin ligase localized in the cytoplasm 
unless recruited to the mitochondria to initiate mitophagy, was analyzed upon 5mM PPG 
treatment of 24 hours. PARKIN’S distribution (red) within the cellular cytoplasm 
appeared augmented upon PPG treatment (Fig. 9A middle bottom panel); however its 
localization to the mitochondria was scarcely detected (Fig. 9A merged bottom panel). 
Live cell imaging using the mitochondrial specific intercalating fluorescent dye 
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MitoTracker confirmed that 5-oxo and PPG treatment of ZR-75-1 cells did not produce 
loss of mitochondrial number with similar mitochondrial fluorescence detected in control 
and treated samples (Fig. 9B). Additional confocal imaging (compressed Z stack) 
displayed PRODH (green) protein intensity diminished (Fig. 9C) while whole cell lysate 
from the same experiment confirms PPG produces significant reduction of PRODH 
levels relative to control and 5-oxo treatment (Fig. 9D). The PRODH competitive 
inhibitor 5-oxo shows no modelling effects on PRODH structure and does not induce 
PRODH protein decay (Fig. 9B, 9D). 
Investigating UPR
mt
 activation by examining PPG influences on various mitochondrial 
stress signals 
In search for markers of unfolded protein response, we examined GRP75, a 75 
kDa Glucose-Regulated protein known to be part of the scaffold connecting the 
endoplasmic reticulum and mitochondria. Confocal microscopy was employed to 
evaluate the localization and interaction between GRP75 (red) and TOM20 (green). 
GRP75, extensively distributed in the mitochondria of control cells, is seen merged with 
TOM20 as a yellow signal (merged top panel); however its intensity is lost upon PPG 
treatment seen as mostly green in merged bottom panel (Fig. 10). Also examined as a 
marker of UPR
mt
, HSP60 mitochondrial chaperone protein levels were upregulated 3-fold 





Figure 10. GRP75 Communication with TOM20 in Mitochondria is disrupted after 24h 
PPG. Top panel untreated ZR-75-1 cells stained for GRP75 (red) and mitochondrial 
TOM20 (green). Bottom panel identical to top panel but cells treated with 5 mM PPG for 
24 hours.  
 
 
Figure 11. ZR-75-1 cells treated with 24h PPG show elevated levels of HSP60. (A) 
Western blot of ZR-75-1 whole cell lysate probed for HSP60 (60kD) and normalized to 
β-actin (~40kD) with C1/C2 control samples. (B) Bar graph quantifying normalized 
HSP60 values relative to β-actin.  
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Investigating PPG influences on mitochondrial protein PRODH through enzymatic 
assays 
The accumulation of the downstream mitochondrial product, NADH, was 
measured in isolated mitochondria from ZR-75-1 cells (control and PPG treated), 
following addition of substrates (proline and malate). Cell treatment with 5mM PPG for 
24 hours led to irreversible inhibition of mitochondrial PRODH with no NADH produced 
when proline was added (red line), while malate oxidation was not affected (Fig. 12). 
Rinsed mitochondria from above experiment showed same results. Control mitochondria 
(blue line) are capable of metabolizing proline and malate, seen as an increase in NADH 
levels.  
 
Figure 12. ZR-75-1 cells vehicle and PPG treated given proline and malate to 
metabolize. Graph displays NADH fluorescence measurements in vehicle (blue) and PPG 
treated (red) cells when proline and malate substrates are added to 96-well plate. 




In Vivo Study Results 
The collaborative Drosophila study between the Benz and Jasper laboratories has 
shown induction of Sluggish-A phenotype following 48 h PPG oral administration to 
flies. Experiments detailed the sluggish-A null mutant flies and their phenotype (16). The 
clear viability of the treated flies exhibiting the identical phenotype as PRODH genetic 
knockout flies previously reported (16) represents our key rationale for undertaking the in 
vivo treatment of mice with PPG. As was shown in the video clip and discussed 
previously, the feeding of PPG to Drosophila flies mimics the “Sluggish-A” phenotype 
implying PPG’s bioavailability and animal tolerance in millimolar concentrations without 
loss of viability or obvious adverse effects. Encouraged by these results in flies, 
preliminary studies using mice were undertaken to assess the consequences of in vivo 
PPG administration. 
Nude mice experiments 
Whole cell lysate and isolated mitochondria of kidneys of PPG-treated mice 
shows a reduction in PRODH protein levels relative to vehicle treated mice. It is 
noteworthy that potential tissue heterogeneity may account for differences in PRODH 




Figure 13. Western analysis of PRODH expression in whole cell lysate from mouse 
kidneys (+/- PPG treatment) shows PRODH level reduction in PPG treated vs vehicle. 
Western blot showing whole cell lysate from frozen mouse kidneys (PTC1797); MCF7-
xenografted nu/nu mice treated with vehicle (974, 975) vs. PPG 50 mg/kg x 3 (qod) in 
saline intravenously (IV925, IV962), intraperitoneally (IP963, IP964) and by oral gavage 
(PO966, PO967). Blot probed for PRODH (67kD) and normalizing mitochondrial protein 
ATP synthase (55kD).  
 
 
Figure 14. Western analysis of PRODH expression in mitochondria isolated from mouse 
kidneys (+/- PPG treatments). Western blot showing isolated mitochondrial from frozen 
mouse kidneys (PTC1797); MCF7-xenografted nu/nu mice treated with vehicle (975) vs. 
PPG 50 mg/kg x 3 (qod) in saline intravenously (IV925) and by oral gavage (PO967). 






Figure 15. Western analysis showing isolated mitochondrial prepared from frozen mouse 
kidneys (PTC1797). MCF7-xenografted nu/nu mice treated with vehicle (975) vs. PPG 50 
mg/kg x 3 (qod) in saline by oral gavage (PO 966 and 967). Blot probed for PRODH 




MCF-7 tumor xenograft study, PTC-1797 
 
Figure 16. PTC-1797 MCF7-xenografted nu/nu. (A) Displays tumor volume 
measurements for nine mice (three per group PO, IV, IP) treated with PPG 50 mg/kg x 3 
(qod); (B) Averages results per group (PO blue line, IV maroon line, IP gray line). Both 
display PPG treatment initiated at day 21 and PPG’s ability to reduce tumor volumes 






Tumor volume (% of initial tumor volume) data collected on nine different MCF-
7 tumor implanted (subcutaneously) mice, whose tumor volumes were tracked over time 
(Fig.16A). At day 10 after tumor implantation, tumor volumes were recorded as 100% 
and varying tumor volumes were tracked by different color lines (intravenously IV 
maroon lines; oral gavage PO blue lines; intraperitoneal IP gray lines). Mice drug 
treatment started at day 21 and every tumor showed volume reduction, except for that 
corresponding to mouse 965, who received PPG via oral gavage. Average tumor volume 
changes (also color coded) display the IV route of drug administration capable of 30% 
reduction in tumor volume, bringing it to the same size as day 10. IP route of drug 
administration showed a 25% reduction in tumor volume from day 10, and PO route of 
drug administration showed a 35% reduction, the most significant decrease in tumor 
volume indicating oral administered of PPG can reduce the volume of a subcutaneously 




MCF-7 tumor xenograft study, PTC-1854 
 
Figure 17. PTC-1854 MCF7-xenografted nu/nu. Graph displays tumor volume 
measurements for two mice treated with nine daily PO doses of PPG (50 mg/kg) – green 
(3840) and turquoise (3880) lines relative to control – blue (3883) line. Dosing started at 
study day 58 and mice were sacrificed at day 66 (unpublished data). 
 
Similarly to PTC-1797, an identical strain of nude mice were implanted with a 
genetically modified clone of MCF-7 cells expressing a mutated (and constitutively 
active) form of ER that enables their tumorigenic growth in the absence of additional 
estradiol supplementation. These MCF/mutER xenografted mice were not treated shortly 
after implantation but only after well-established tumor growth (i.e. tumor volume >400 
mm
3
). At that time, mice were treated with nine daily doses of either vehicle (mouse 
3883) or 50mg/kg of PPG (mice 3840 and 3880), via oral gavage, starting at day 58. All 
three mice tolerated their oral treatments well, showing no significant change in weight 
and continuously displaying healthy behaviors.  
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Tumor volume (% of initial tumor volume) data was collected until mouse 
sacrifice and tumor excision at day 66. While the control animal at this late stage of 
tumor growth showed exponential tumor growth after day 58, the PPG treated animals 
showed much more blunted growth after day 58, suggesting some PPG effect. However, 
when looking at the relative gain in tumor volume over the nine treatment days, both the 
PPG-treated and the vehicle control groups showed nearly 1.4-fold increases in tumor 
volume, indicating no significant antitumor effect of PPG on these well-established 
MCF-7 tumor xenografts (Fig. 17). While normal organs were not saved from this 
particular study, comparison of the three xenografted MCF-7/ERmut tumors isolated 
mitochondria showed reduced PRODH protein levels in PPG-treated mice (3880, 3840) 
relative to control (3883) (Fig 18). Lastly, using a goat anti-mouse light chain antibody 
helped eliminate problems with mouse heavy chain bands.   
 
Figure 18. Western Analysis of Isolated Mitochondria from frozen Mice Tumors 
(PTC1854) shows PRODH level reduction in PPG treated vs vehicle. Western blot of 
technical replicates showing isolated mitochondrial prepared from frozen mouse tumors 
(PTC1854); MCF7-xenografted nu/nu mice treated with vehicle control (3883) vs. PPG 
50 mg/kg x 9 daily doses in saline by oral gavage (3840, 3880). Blot probed for PRODH 





The pursuit for PRODH inhibitors goes back nearly 40 years when this was 
considered a possible approach to eradicate tsetse flies and prevent African 
trypanosomiasis (34). The role of proline dehydrogenase (PRODH) in cancer progression 
has been previously explored in vivo (8, 19, 31) and the metabolism of proline by 
PRODH has been proposed to produce mitochondrial ROS and promote apoptosis in 
cancer cells (8, 21). However, former studies in the Benz laboratory provided evidence 
that PRODH can function to produce ATP, vital to cell survival, thus motivating our 
efforts to investigate PRODH inhibitors as cancer therapeutic agents. This project extends 
previous results targeting PRODH in various breast cancer cell lines by addressing both 
the mechanistic questions about mitochondrial stress induced by in vitro cell line 
treatments with the suicide PRODH inhibitor, PPG, as well as the in vivo feasibility of 
systemically administering PPG as a potential therapeutic. The use of confocal 
microscopy was essential to detect mitochondrial PRODH decay in ZR-75-1 breast 
cancer cells following PPG treatment without loss of mitochondria number (Fig. 7, 8, 
9C). Additionally, using both confocal microscopy and Western analysis, these in vitro 
results are extended to demonstrate that PPG treatment promotes UPR
mt
 activation as 
assessed by cellular response of the stress proteins PARKIN, GRP75 and HSP60 (Fig. 
9A, 10, 11).  Finally, as a first step in addressing the potential bioavailability and in vivo 
effectiveness of PPG, results from mouse studies presented here support PPG as an 
effective biologic agent. 
The use of immunocytochemistry analysis provided a new tool to examine the 
PRODH decay following PPG treatment (Fig. 7, 8). In all of these studies, TOM20 
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served as an excellent mitochondrial marker since it is a member of the TOM complex in 
the outer membrane of the mitochondria and responsible for recognizing and 
translocating mitochondrial proteins from the cytosol. TOM20 remained unchanged 
throughout PPG treatments, besides, without it the mitochondria would not survive. 
Initial in vitro results that PPG reduces PRODH protein intensity combined with 
mitochondrial assays (Fig. 5, 12) and structural modeling suggested PPG covalently 
modifies PRODH’s FAD moiety causing pocket distortion (Fig. 4, 5, 6), which might be 
responsible for PRODH’s disappearance within 24 hours (Fig. 6, 7, 8, 9C). Moreover, 
PPG was shown not to influence the levels of other mitochondrial proteins such as the 
complex-1 mitochondrial protein NDUFS1 (Fig. 6, 8) and complex-3 mitochondrial 
protein Rieske FeS [data not shown], as well as the extra-mitochondrial (cytosolic) FAD-
containing protein methylenetetrahydrofolate reductase (MTHFR), structurally very 
similar to PRODH (Fig. 6, 8). It is noteworthy that two different PRODH antibodies were 
intentionally used, a mouse monoclonal and a rabbit polyclonal, with both antibodies 
producing similar results further validating these observations (Fig. 7, 8). Taken together, 
these results indicate PPG induces PRODH protein loss without loss of concurrent 
mitochondrial structures, while the similar TOM20 signal intensity between control and 
treated cells reveals that an equivalent number of mitochondria were present, proposing 
PPG does not induce loss of mitochondrial structures via mitophagy.  
To investigate the possibility that PPG induces mitophagy, examination of 
PARKIN’s localization (red) within the cellular cytoplasm appeared augmented upon 
PPG treatment possibly as PARKIN is recruited to the cytoplasm from the endoplasmic 
reticulum; however these results demonstrated little or no recruitment of PARKIN to the 
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mitochondria following PPG treatment, suggesting that mitophagy was not induced by 
PPG (Fig. 9A).  As a caveat to this, Parkin-independent mitophagy scenarios have been 
reported (35) and in that regard cells may be undergoing mitophagy in a non-parkin 
dependent manner or on a time scale longer than the current experiments explored. In 
addition, it is also possible that if mitochondria are in fact being consumed by mitophagy, 
their synthesis compensates for this loss and explains our observation of no net change in 
TOM20 levels and intensity. Thus, using confocal microscopy to assess mitochondrial 
number, represented by TOM20 intensity, we determined that PPG induced no noticeable 
loss of mitochondrial number, while mitochondrial PRODH intensity was significantly 
diminished. Additionally, live cell imaging of cells treated with 5-oxo and PPG (Fig. 9B) 
shows similar mitochondrial fluorescence detected relative to control suggesting these 
PRODH inhibitors have no impact on mitochondrial number. Equally important, in 
response to mitochondrial stress, PARKIN binds to TOM20 in the mitochondrial outer 
membrane, and when activated, PARKIN adds ubiquitin chains to proteins to signal their 
mitochondrial degradation via the proteolytic pathway. Since PARKIN is not 
significantly affected by PPG treatment, that constitutes another piece of evidence 
consistent with absence of mitophagy, instead, arguing for activation of the mitochondrial 
unfolded protein response (UPR
mt
) pathway resulting in PRODH degradation.  
This activation of UPR
mt
 is a stress response initiated when misfolded proteins 
within the mitochondria overwhelm both its chaperone refolding and protein degrading 
capacities.  In this regard, UPR
mt
 activation is a complex issue with the upregulation and 
coordination of many mitochondrial chaperone and proteases proteins such as HSP60 and 
Clp, respectively. As assessing UPR
mt
 activation by determining changes to these 
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proteins by confocal microscopy presented a technically challenging problem, examining 
the mitochondria’s association with the membrane network of the endoplasmic reticulum 
was undertaken. Numerous studies have demonstrated that disruption of MAMs 
(mitochondrial associated membranes) occurs under conditions of mitochondrial stress 
and is also seen in many diseases such as cancers and Alzheimer’s (36, 37). To examine 
PPG’s capacity to promote the UPR
mt
, we looked for evidence of alteration or disruption 
of the mitochondria’s association with the endoplasmic reticulum (ER) using GRP75 as a 
marker. GRP75 is a scaffold protein anchoring MAMs to the mitochondria as they 
facilitate calcium homeostasis and fatty acid metabolism. Mainly a mitochondrial protein, 
GRP75 is also present in other organelles, and it has been reported to be disrupted under 
stress conditions, no longer making a communication bridge between ER and 
mitochondria (36, 37). In our control experiments, GRP75 co-localized with TOM20 in 
the mitochondria, but following PPG treatment, the intracellular distribution of GRP75 
intensity was diminished relative to TOM20 (Fig. 10) suggesting loss of mitochondria 
homeostasis by induction of mitochondrial stress and likely activation of UPR
mt
. To 
further validate the activation of UPR
mt
, levels of the mitochondrial chaperone protein 
HSP60, another marker of mitochondrial stress, was investigated and shown to be 
upregulated following PPG treatment of breast cancer cells (Fig. 11A). While PPG 
induced a 3-fold increase in HSP60 levels compared to vehicle, the competitive inhibitor 
5-oxo had essentially no influence upon HSP60 levels (Fig. 11B). Altogether, it appears 
that the covalent distortion of PRODH structure by the suicide inhibitor PPG is a novel 
effector of UPR
mt
 and our hypothesis that PPG induces structural distortions of PRODH 
and promotes a mitochondrial stress response (UPR
mt
) is supported.    
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Next, working closely with our Buck Institute collaborator, Martin Brand, PhD, 
we have optimized our mitochondrial preparation technique and developed a bioassay 
capable of indirectly measuring inhibitor activity of mitochondrial PRODH by 
monitoring NADH levels upon substrate addition. While the known PRODH inhibitor L-
THFA (at 5mM) produced approximately 70% reduction in proline’s NADH generating 
capacity (27), and the 5-oxo competitive inhibitor identified by our modeling studies 
(Fig. 4A) produced a 95% reduction (at 5mM) in proline’s NADH generating capacity, 
we compared those responses to that of the PRODH suicide inhibitor, N-propargylglycine 
(PPG). Our hypothesis that mitochondria isolated from PPG treated ZR-75-1 cells are 
unable to metabolize proline although able to metabolize malate was validated (Fig. 5, 
12). In contrast, the effects of a competitive PRODH inhibitor, such as 5-oxo, are 
completely lost during the washout step. Thus, PPG treatment leads to immediate and 
irreversible loss of PRODH’s enzymatic activity followed by its time-dependent selective 
degradation within the mitochondria of ZR-75-1 cells.  
A crucial requirement for any cancer therapeutic is a drug’s bioavailability and 
efficacy of action. In that regard, initial experiments with Drosophila flies shown in the 
video link demonstrate that feeding flies PPG at 5mM in sucrose solution recapitulated 
the “Sluggish A” phenotype characterized by PRODH knockdown or its genetic loss, and 
the inability to generate sufficient wing muscle ATP to power flight.  Given the 
tolerability and bioavailability of orally administered PPG to flies, we extended our 
studies of PPG bioavailability and efficacy to mouse models. Kidney whole cell lysate 
and isolated kidney mitochondria from PPG-treated mice revealed lower PRODH protein 
levels relative to control (Fig. 11, 13, 14), consistent with our in vitro studies and in vivo 
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evidence in flies. PPG given orally (PO) to mice appeared optimally bioavailable and 
capable of inducing PRODH loss (Fig.14) when compared to other administration routes.  
PPG treatment promotes in vivo loss of cellular PRODH in treated mice, 
particularly when assessed in intact isolated mitochondria that gives a stronger PRODH 
signal compared to the whole cell lysate, with ten times better results. Moreover, 
mitochondria isolated from frozen tumors excised from PPG-treated mice showed 
approximately one fifth of the PRODH levels detected in the tumor of control mice (Fig. 
18). Even considering variability among animals, there is an apparent tumor volume 
reducing effect of PPG in these xenografted mice. Finally, as differential blood flows to 
organs versus xenografted tumors and heterogeneous levels of PRODH expression within 
different organ compartments may vary (kidney cortex vs. collecting system), variations 
were expected and observed between PRODH expression levels, and the effect of PPG on 
those, between independent preparations from the same frozen tissue material. 
Altogether, these results also led us to conclude that MCF-7 tumor xenografts are 
affected by PPG, but not particularly growth-limited by its administration in vivo, even 
though this cell line is known to be relatively insensitive to PRODH inhibitors due to low 
PRODH levels. Yet, the primary purpose of both these in vivo studies was to determine if 
systemically administered PPG could be detected in either the implanted tumor masses or 
normal mouse organs and we have revealed PRODH levels affected by PPG in both 
instances.  
Reduction of the MCF-7 xenograft tumor volumes suggested that PPG not only 
reached at least a portion of the malignant cells resulting in decreased tumor PRODH 
levels (Fig. 18), but also produced detectable growth inhibiting effects of these cancers. 
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Such effects were most prominent when PPG was administered soon after tumor 
formation, while larger tumor masses seemed less affected suggesting limitations 
imposed by loss of vascular access. Recently, other investigators have begun exploring 
the in vivo potential of inhibiting PRODH expression in tumors, albeit using a less 
effective competitive PRODH inhibitor, L-THFA. Elia et al looked at tumors and 
metastases in 6-week old female BALB/c mice orthotopically inoculated with 4T1 or 
EMT6.5 mammary tumor cells. Primary breast tumors in their mouse models 
spontaneously produced metastases to the lungs in a short time with 100% penetrance. 
Primary tumors and body weight were monitored following PRODH inhibitor 
administration, without any observed adverse effects on healthy tissue and organ function 
(31). Their mouse studies, similarly to ours, showed minimal tumor volume changes in 
the large primary tumor implants but a significant reduction in the number of new lung 
metastases developed over the course of treatment. The employed 30mg/kg dose of L-
THFA, relative to our 50mg/kg PPG doses, were given daily by intraperitoneal injections 
only, and no other administration route. Since the ultimate goal of such projects is to 
develop a drug therapy that might eventually be translated to human patients, it is vital to 
compare multiple routes of drug administrations, especially since intraperitoneal drug 
injection is not a typical or well accepted mode of anticancer drug administration in 
humans. Our project advances the field of cancer by comparing three different 
administration routes and testing multiple drug doses, concluding that oral and 
intravenous dosing are optimal for a drug candidate like PPG.   
As a final point, cancer cell dependence on ATP production supports the 
development of therapeutic agents capable of targeting glutamate and ATP production, 
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thereby limiting the cancer’s energy production and metabolic building blocks for 
macromolecular synthesis. Evidence presented here provides new mechanistic insight 
into PPG’s role as a novel mitochondrially targeted anticancer agent with a unique 
mechanism of action, resulting in induction of mitochondrial stress and activation of the 
mitochondrial unfolded protein response (UPR
mt
), depriving cells of PRODH by 





This project’s primary objectives were to address the mitochondrial consequences 
induced by the PRODH suicide inhibitor PPG, and the in vivo feasibility and 
bioavailability of administering PPG to live animals. These objectives were accomplished 
and our hypotheses validated. When reflecting on PPG’s irreversible binding mechanism 
to PRODH, we have observed selective degradation of PRODH protein levels without 
loss of other mitochondrial proteins or mitochondria number, supporting a structural 
model and molecular mechanism of action in which PRODH distortion induces 
mitochondrial stress and activates its unfolded protein response, rather than mitophagy. 
In the worldwide search for new mitochondria-targeted cancer therapeutics, PPG offers a 
unique chemical tool to advance knowledge about mitochondrial biology as well as 
develop a new class of mitochondrial therapeutics.  
When comparing the in vivo effects of PPG on normal kidneys and implanted tumors, 
our results provide evidence that PPG can be systemically administered by mouth and 
produce a pharmacodynamic effect at a distant mitochondrial site. Despite our need for 
an alternative PRODH expressing tumor model more sensitive to PRODH inhibition to 
conduct more extensive in vivo preclinical studies, we are confident our findings provide 
new and compelling rationale to pursue additional in vivo studies with our prototype 
PRODH suicide inhibitor, PPG. 
PPG creates a non-hydrolysable bond within PRODH’s catalytic site essentially 
preventing the entire subsequent cascade of events, including glutamate production vital 
for energy generation to fuel cancer cell survival. This complexed study touched upon 
many aspects of mitochondrial energetics and it provides a promising first step in the 
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investigation of PPG and its effects on cancer, hopefully helping countless people due to 





1. Benz, C., Scott, G., (2014) Grant proposal: Targeting proline dehydrogenase (PRODH) 
induces synthetic lethal interactions with p53 restoring drugs and glutaminase (GLS1) 
inhibitors in breast cancer. A1 resubmission of grant proposal R21-CA187523 
“Targeting proline metabolism produces a synthetic lethal interaction with p53 
restoration.” 
2.  Gary K. Scott, Justine Rutter, Katya Frazier, Daniel Rothschild, Christina Yau, 
Christopher Benz. A new anticancer strategy based on inhibiting mitochondrial 
proline dehydrogenase (PRODH) and exploiting synthetic lethal interactions with p53 
restoration and/or glutaminase (GLS1) inhibition [abstract]. In: Proceedings of the 
106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 
18-22; Philadelphia, PA. Philadelphia (PA): AACR; 2015. Abstract nr 5402 
3.  Andrea R. Daniel, Angela L. Gaviglio, Todd P. Knutson, Julie H. Ostrander, Douglas 
Yee, Carol A. Lange. Unliganded progesterone receptors augment estrogen-induced 
growth of breast cancer cells via co-regulation of estrogen receptor target genes 
[abstract]. In: Proceedings of the 104th Annual Meeting of the American Association 
for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; 
Cancer Res 2013; 73 (8 Suppl.): Abstract nr 3572. doi:10.1158/1538-7445.AM2013-
3572 
4.  Manna, S., & Holz, M. K. (2016). Tamoxifen action in ER-negative breast cancer. 
Signal Transduction Insights, 5, 1-7. 10.4137/STI.S29901 [doi] 
5. Neill, P., Martin Lesley‐Ann, & Mitch, D. (2013). Biomarkers for the clinical 
management of breast cancer: International perspective. International Journal of 
51 
 
Cancer, 133(1), 1-13. 10.1002/ijc.27997 Retrieved from 
https://doi.org/10.1002/ijc.27997 
6. Cheang, M. C., Voduc, D., Bajdik, C., Leung, S., McKinney, S., Chia, S. K., Nielsen, 
T. O. (2008). Basal-like breast cancer defined by five biomarkers has superior 
prognostic value than triple-negative phenotype. Clinical Cancer Research: An 
Official Journal of the American Association for Cancer Research, 14(5), 1368-1376. 
10.1158/1078-0432.CCR-07-1658 [doi] 
7.  Sorlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Borresen-
Dale, A. L. (2001). Gene expression patterns of breast carcinomas distinguish tumor 
subclasses with clinical implications. Proceedings of the National Academy of 
Sciences of the United States of America, 98(19), 10869-10874. 
10.1073/pnas.191367098 [doi] 
8. Liu W, Phang JM. Proline dehydrogenase (oxidase), a mitochondrial tumor suppressor, 
and autophagy under the hypoxia microenvironment. Autophagy 8: 14071409, 2012. 
9. Yoshida, G.J. Metabolic reprogramming: the emerging concept and associated 
therapeutic strategies. http://jeccr.biomedcentral.com/articles/10.1186/s13046-015-
0221-y (2015) 
10. Donald SP, Sun XY, Hu CA, Yu J, Mei JM, Valle D, Phang JM. Proline oxidase, 
encoded by p53-induced gene-6, catalyzes the generation of proline-dependent 
reactive oxygen species. Cancer Res. 2001 Mar 1; 61(5):1810-5.  
11. Liu W, Le A, Hancock C, Lane A, Dang CV, Phang JM. Reprogramming of proline 
and glutamine metabolism contributes to the proliferative and metabolic responses 
regulated by oncogenic transcription factor c-MYC. Proc Natl Acad Sci USA 109: 
52 
 
8983-8988, 2012.  
12. Servet C, Ghelis T, Richard L, Zilberstein A, Savoure A. Proline dehydrogenase: a key 
enzyme in controlling cellular homeostasis. Frontiers in Bioscience 17: 607-620, 2012.  
13. Lee YH, Nadaraia S, Gu D, Becker DF, Tanner JJ. Structure of the proline 
dehydrogenase domain of the multifunctional PutA flavoprotein. Nat Struct Biol 
10:109-114, 2003.  
14. Liang, X., Zhang L., Natarajan SK., Becker DF. (2013, September 20). Proline 
Mechanisms of Stress Survival. Antioxidants & Redox Signaling, 19(9), 998-1011. 
doi:10.1089/ars.2012.5074 
15. Neve RM, Chin K, Fridlyand J, et al. A collection of breast cancer cell lines for the 
study of functionally distinct cancer subtypes. Cancer Cell 10: 515-527, 2006.  
16. Hayward, DC et al. “The Sluggish-A Gene of Drosophila Melanogaster Is Expressed 
in the Nervous System and Encodes Proline Oxidase, a Mitochondrial Enzyme 
Involved in Glutamate Biosynthesis.” Proceedings of the National Academy of 
Sciences of the United States of America 90.7 (1993): 2979–2983. Print. 
17. Polyak K, et al. A model for p53-induced apoptosis. Nature 389:300–305, 1997.  
18. Pandhare J, Cooper SK, Donald SP, Phang JM. Regulation and function of proline 
oxidase under nutrient stress. J Cell Biochem 107: 759-768, 2009.  
19. Phang JM, et al. The proline regulatory axis and cancer. Front Oncol 2: 60, 2012. 
20. Liu W, Glunde K, Bhujwalla ZM, Raman V, Sharma A, Phang JM. Proline oxidase 
promotes tumor cell survival in hypoxic tumor microenvironments. Cancer Res 72: 
36773686, 2012. 
21. Gonçalves RL, Rothschild DE, Quinlan CL, Scott GK, Benz CC, Brand MD. Sources 
53 
 
of superoxide/H202 during mitochondrial proline oxidation. Redox Biology 2 (2014): 
901-909. 
22. Gary K. Scott, Beatrice C. Becker, Katya Frazier, Christina Yau, Christopher Benz. 
Targeting mitochondrial proline dehydrogenase (PRODH) with a mechanism-based 
irreversible inhibitor induces selective mitochondrial stress before cancer cell death 
[abstract]. In: Proceedings of the 107th Annual Meeting of the American Association 
for Cancer Research; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; 
2017. Abstract nr 1489 
23. Rivlin, Noa et al. Mutations in the p53 Tumor Suppressor Gene: Important Milestones 
at the Various Steps of Tumorigenesis. Ed. Arnold J. Levine. Genes & Cancer 2.4 
(2011): 466–474. PMC. Web. 13 Oct. 2016. 
24. Benz, C. (2008). Impact of aging on the biology of breast cancer. Critical Reviews in 
Oncology/hematology, 66(1), 65–74. http://doi.org/10.1016/j.critrevonc.2007.09.001 
25. Christina Yau, Bianca Gabriel, Gary Scott, Martin Brand, and Christopher C. Benz. 
Global metabolomics profiles distinguish malignant from non-malignant human 
mammary epithelial cell responses to endogenous p53 upregulation by MDM2 
antagonism [abstract]. In: Proceedings of the 103rd Annual Meeting of the American 
Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): 
AACR; Cancer Res 2012; 72 (8 Suppl.): Abstract nr 5160. doi:1538-7445.AM2012-
5160. 
26. Buck Institute for Research on Aging (2014). Inhibition of Proline Catabolism for the 
Treatment of Cancer and other Therapeutic Applications. U.S. Patent No. 62/079,382 
filed Nov. 13, 2014. California: U.S.  
54 
 
27. T.A. White, N. Krishnan, D.F. Becker, J.J. Tanner. Structure and kinetics of 
monofunctional proline dehydrogenase from Thermus thermophiles. Journal of 
Biological Chemistry, 282 (2007), pp. 14316-14327, 10.1016/j.redox.2014.07.003 
17344208 
28. Yun, Jeanho et al. Mitohormesis. Cell Metabolism, Volume 19, Issue 5, 757 – 766. 
29. Jensen MB, Jasper H. Mitochondrial proteostasis in the control of aging and longevity. 
Cell Metabolism. 2014; 20: 214-225. doi: 10.1016/j.cmet.2014.05.006. 
30. Gargano JW, Martin I, Bhandari P, Grotewiel MS. Rapid iterative negative geotaxis 
(RING): a new method for assessing age-related locomotor decline in Drosophila. Exp 
Gerontol. 2005;40: 386-395. doi: S0531-5565(05)00034-3 [pii]. 
31. Elia, Ilaria et al. “Proline Metabolism Supports Metastasis Formation and Could Be 
Inhibited to Selectively Target Metastasizing Cancer Cells.” Nature Communications 
8 (2017): 15267. PMC. Web. 20 Oct. 2017. 
32. Schindelin, J., et al. (2012), "Fiji: an open-source platform for biological-image 
analysis", Nature methods 9(7): 676-682, PMID 22743772, doi:10.1038/nmeth.2019, 
on Google Scholar. 
<http://www.nature.com/nmeth/journal/v9/n7/full/nmeth.2019.html> 
33. Scott, GK., et al. “ERpS294 Is a Biomarker of Ligand or Mutational ERα Activation 
and a Breast Cancer Target for CDK2 Inhibition.” OncoTarget 8.48 (2017): 83432–
83445. PMC. Web. 11 Dec. 2017.  
34. Tritsch D, Mawlawi H, Biellmann JF. Mechanism-based inhibition of proline 
dehydrogenase by proline analogues. Biochim Biophys Acta 1202: 77-81, 1993 
35. Villa, Elodie et al., Parkin-Independent Mitophagy Controls Chemotherapeutic 
55 
 
Response in Cancer Cells. Cell Reports , Volume 20 , Issue 12 , 2846 – 2859 
36. López-Crisosto, C., Bravo-Sagua, R., Rodriguez-Peña, M., Mera, C., Castro, P. F., 
Quest, A. F. G., Lavandero, S. (2015). ER-to-mitochondria miscommunication and 
metabolic diseases//doi.org/10.1016/j.bbadis.2015.07.011 Retrieved from 
http://www.sciencedirect.com/science/article/pii/S0925443915002033 
37. Raturi, A., & Simmen, T. (2013). Where the endoplasmic reticulum and the 
mitochondrion tie the knot: The mitochondria-associated membrane 
(MAM)//doi.org/10.1016/j.bbamcr.2012.04.013 Retrieved from 
http://www.sciencedirect.com/science/article/pii/S0167488912001048 
38. Bender H-U, Almashanu S, Steel G, Hu C-A. Functional Consequences of PRODH 
Missense Mutations. Am J Hum Genet 76: 409– 420, 2005.  
39. Benz, C., Jasper, H., (2011) Calico Project proposal submitted: Targeting Proline 
Catabolism to Activate the UPR
mt
 Response as a Cancer-Aging Intervention  
40. B.A. Baban, M.P. Vinod, J.J. Tanner, D.F. Becker. Probing a hydrogen bond pair and 
the FAD redox properties in the proline dehydrogenase domain of Escherichia coli 
PutA Biochimica et Biophysica Acta, 1701 (2004), pp. 49-59, 
10.1016/j.redox.2014.07.003 15450175 
41. Hargrove JW. Amino acid metabolism during flight in tsetse flies. J Insect Physiol 
22:309-313, 1976.  
42. Naser, A. Anjum (2014). Plant Adaptation to Environmental Change: Significance of 
Amino Acids and their Derivatives (Pages 70-71). Boston, MA: CAB International. 
43. Christina Yau, Rachel Puckett, Akos A. Gerencser, Martin D. Brand, and Christopher 
C. Benz. Wildtype p53 upregulation induces contrasting bioenergetics and metabolic 
56 
 
responses in malignant and nonmalignant mammary epithelial cells [abstract]. In: 
Proceedings of the 102nd Annual Meeting of the American Association for Cancer 
Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011; 
71 (8 Suppl.): Abstract nr 3797. doi:10.1158/1538-7445.AM2011-3797 
44. P.Y. Scaraffia, M.A. Wells. Proline can be utilized as an energy substrate during flight 
of Aedes aegypti females. Journal of Insect Physiology, 49 (2003), pp. 591-601, 
10.1016/j.redox.2014.07.003 12804719 
45. M.A. Moxley, J.J. Tanner, D.F. Becker. Steady-state kinetic mechanism of the proline: 
ubiquinone oxidoreductase activity of proline utilization A (PutA) from Escherichia 
coli. Archives of Biochemistry and Biophysics, 516 (2011), pp. 113-120, 
10.1016/j.redox.2014.07.003 22040654 
46. N. Krishnan, D.F. Becker. Oxygen reactivity of PutA from Helicobacter species and 
proline-linked oxidative stress. Journal of Bacteriology, 188 (2006), pp. 1227-1235, 
10.1016/j.redox.2014.07.003 16452403 
47. Wei Liu and James M. Phang (2013), CHAP Oncogene and Cancer - From Bench to 
Clinic: MiRNA and Proline Metabolism in Cancer, Dr. Yahwardiah Siregar (Ed.), 
InTech, DOI: 10.5772/55139. Available from: 
https://mts.intechopen.com/books/oncogene-and-cancer-from-bench-to-clinic/mirna-
and-proline-metabolism-in-cancer 
